肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展

doi:10.11904/j.issn.1002-3070.2022.06.006

Abstract

Abstract: Gut microbiota is the general term for microorganisms that live in the intestine.The microbiota is affected by many factors such as the host's diet and drugs.At the same time, the microbiota can also participate in the regulation of the host's immune status.At present, some studies have confirmed that the intestinal flora is related to the efficacy and adverse reactions of anti-tumor immunotherapy, and regulating the flora can improve the efficacy of immunotherapy, but the specific mechanism is still unclear.This article systematically reviews the current research progress and shortcomings of gut microbiota and tumor immunotherapy.

Key words: Intestinal flora, Immunotherapy, Fecal microbiota transplantation

CLC Number:

CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions[J]. Journal of Practical Oncology, 2022, 36(6): 520-525.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.06.006

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I6/520

References

1 Xu K,Jiang B.Analysis of mucosa-associated microbiota in colorectal cancer[J].Med Sci Monit,2017,23:4422-4430.
2 Qi YF,Sun JN,Ren LF,et al.Intestinal microbiota is altered in patients with gastric cancer from Shanxi province,china[J].Dig Dis Sci,2019,64(5):1193-1203.
3 Peng Z,Cheng S,Kou Y,et al.The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer[J].Cancer Immunol Res,2020,8(10):1251-1261.
4 Routy B,Le Chatelier E,Derosa L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Science,2018,359(6371):91-97.
5 Derosa L,Routy B,Thomas AM,et al.Intestinal akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer[J].Nat Med,2022,28(2):315-324.
6 Lee KA,Thomas AM,Bolte LA,et al.Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma[J].Nat Med,2022,28(3):535-544.
7 McCulloch JA,Davar D,Rodrigues RR,et al.Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1[J].Nat Med,2022,28(3):545-556.
8 Kespohl M,Vachharajani N,Luu M,et al.The microbial metabolite butyrate induces expression of Th1-associated factors in CD4(+)T cells[J].Front Immunol,2017,8:1036.
9 Luu M,Weigand K,Wedi F,et al.Regulation of the effector function of CD8(+)T cells by gut microbiota-derived metabolite butyrate[J].Sci Rep,2018,8(1):14430.
10 Bachem A,Makhlouf C,Binger KJ,et al.Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+)T cells[J].Immunity,2019,51(2):285-297.
11 He Y,Fu L,Li Y,et al.Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+)T cell immunity[J].Cell Metab,2021,33(5):988-1000.
12 Nomura M,Nagatomo R,Doi K,et al.Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors[J].JAMA Netw Open,2020,3(4):e202895.
13 Coutzac C,Jouniaux JM,Paci A,et al.Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer[J].Nat Commun,2020,11(1):2168.
14 Mager LF,Burkhard R,Pett N,et al.Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J].Science,2020,369(6510):1481-1489.
15 Vernocchi P,Gili T,Conte F,et al.Network analysis of gut microbiome and metabolome to discover microbiota-linked biomarkers in patients affected by non-small cell lung cancer[J].Int J Mol Sci,2020,21(22):8730.
16 Gopalakrishnan V,Spencer CN,Nezi L,et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J].Science,2018,359(6371):97-103.
17 Matson V,Fessler J,Bao R,et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J].Science,2018,359(6371):104-108.
18 Jin Y,Dong H,Xia L,et al.The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with nsclc[J].J Thorac Oncol,2019,14(8):1378-1389.
19 Zheng Y,Wang T,Tu X,et al.Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J].J Immunother Cancer,2019,7(1):193.
20 Usyk M,Pandey A,Hayes RB,et al.Bacteroides vulgatus and bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma[J].Genome Med,2021,13(1):160.
21 Chau J,Yadav M,Liu B,et al.Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer[J].BMC Cancer,2021,21(1):808.
22 Liu W,Ma F,Sun B,et al.Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors,a real-world study[J].Front Immunol,2021,12:756872.
23 Tan B,Chen MJ,Guo Q,et al.Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events[J].Thorac Cancer,2021,12(12):1814-1823.
24 Chaput N,Lepage P,Coutzac C,et al.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J].Ann Oncol,2017,28(6):1368-1379.
25 Andrews MC,Duong CPM,Gopalakrishnan V,et al.Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade[J].Nat Med,2021,27(8):1432-1441.
26 Feuerstadt P,Louie TJ,Lashner B,et al.SER-109,an oral microbiome therapy for recurrent clostridioides difficile infection[J].N Engl J Med,2022,386(3):220-229.
27 Tomita Y,Ikeda T,Sakata S,et al.Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer[J].Cancer Immunol Res,2020,8(10):1236-1242.
28 Dizman N,Meza L,Bergerot P,et al.Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma:a randomized phase 1 trial[J].Nat Med,2022.28(4):704-712.
29 Baruch EN,Youngster I,Ben-Betzalel G,et al.Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients[J].Science,2021,371(6529):602-609.
30 Davar D,Dzutsev A K,McCulloch J A,et al.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J].Science,2021,371(6529):595-602.
31 Ramakrishna C,Corleto J,Ruegger PM,et al.Dominant role of the gut microbiota in chemotherapy induced neuropathic pain[J].Sci Rep,2019,9(1):20324.
32 Derosa L,Routy B,Fidelle M,et al.Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients[J].Eur Urol,2020,78(2):195-206.
33 Lv J,Jia Y,Li J,et al.Gegen qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment[J].Cell Death Dis,2019,10(6):415.

[1]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[2]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[3]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[4]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[5]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[6]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[7]	TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme [J]. Journal of Practical Oncology, 2022, 36(3): 278-282.
[8]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[9]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[10]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.
[11]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.
[12]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[13]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[14]	WANG Hengmin, ZHAO Qi, WU Huaxing. Research progress of fecal microbiota transplantation in cancer treatment [J]. Journal of Practical Oncology, 2021, 35(5): 468-471.
[15]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.

Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments